Business
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation NEWTON, Mass., Nov. 2, 2023 /PRNewswire/ -- Karyopharm Therapeutics
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation\nNEWTON, Mass., Nov. 2, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts that include selinexor data in myelofibrosis (MF) have been selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12, 2023, in San Diego, CA. The data include an oral presentation featuring long-term efficacy results from the Phase 1 open-label, dose-escalation study of selinexor in combination with ruxolitinib in patients with treatment-naïve MF.\n\n \n \n \n \n \n \n\n \n\"We are pleased to have a number of MF presentations at ASH, which underscore the potential of selinexor to deliver meaningful benefit for patients with this disease,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. \"These presentations demonstrate our commitment and substantial progress toward our goal of improving long-term outcomes for patients and addressing important areas of unmet need.\"\nDetails for the ASH 2023 abstracts are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nSelinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification\nOral\n622\nSunday, December 10th, 2023 5:15 pm\nA Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)\nPoster\n3209\nSunday December 10th, 2023 6:00-8:00 pm\nA Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)\nPoster\n3211\nSunday December 10th, 2023 6:00-8:00 pm\n \nAbout XPOVIO® (selinexor)\nXPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology ind...